Privacy Policy
Signals Blog

Contributors

Categories

The Canadian regulatory system for cell and gene therapies

Aileen J. Zhou brings over a decade of experience in biotech and medical device regulatory affairs. She is an active member and contributing author of the Regulatory Affairs Professional Society (RAPS) and Alliance for Regenerative Medicine’s Regulatory and CMC...

Comparing two snapshots of RM taken a decade apart

When Signals first burst onto the scene in 2012, the potential of the regenerative medicine industry still hadn’t set in for many. When the Alliance for Regenerative Medicine (ARM) published its first state of the industry report in 2012, the ARM chairman at the time,...

Genetically engineering cures for sickle cell disease

If I were to ask you to think of a genetic disease that should be a priority for gene therapy research, you might say breast cancer, Huntington’s, or cystic fibrosis. And these are all great candidates. But I’d say you’re missing a big one. Sickle cell disease (SCD)...